Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00483457 · ClinicalTrials.gov registry record
Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- 33
- Enrollment target
NCT00483457 is a clinical trial that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 33 participants.
The verdict
NCT00483457 has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tissue and blood in the laboratory from patients with cancer receiving epidermal growth factor receptor (EGFR) inhibitors may help doctors understand the effects of EGFR inhibitor therapy in the skin. PURPOSE: This laboratory study is looking at the effects of EGFR inhibitors in the skin of cancer patients.
Interventions
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- DRUG enzyme inhibitor therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00483457
The ClinicalTrials.gov registry entry for NCT00483457 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00483457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00483457 about?
NCT00483457 is a clinical study titled "Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients". RATIONALE: Studying samples of tissue and blood in the laboratory from patients with cancer receiving epidermal growth factor receptor (EGFR) inhibitors may help doctors understand the effects of EGFR inhibitor therapy in the skin. PURPOSE: This laboratory study is looking at the effects of EGFR in...
What is the current status of trial NCT00483457?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2006-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00483457?
The interventions under investigation include: protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), enzyme inhibitor therapy (DRUG).
Who is sponsoring clinical trial NCT00483457?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.